Wilms6 Cells

Categories: Kidney cancer cell lines Description: The Wilms6 cell line was established from a primary Wilms tumor in a pediatric patient with a germline WT1 mutation. This cell line is defined by a homozygous nonsense mutation in the WT1 gene (c.1168 C>T, p.R390X), which results in a truncated and non-functional WT1 protein. WT1 is a critical regulator of kidney development, and its loss is strongly associated with Wilms tumor, particularly in cases displaying mesenchymal differentiation. The Wilms6 cell line is an important model for studying the tumorigenic effects of complete WT1 loss, particularly in the context of tumors that exhibit both epithelial and mesenchymal characteristics. Wilms6 cells also carry a mutation in the CTNNB1 gene, specifically affecting serine 45 (p.S45F), a key site for phosphorylation that regulates beta-Catenin degradation. This mutation leads to the stabilization and nuclear accumulation of beta-Catenin, resulting in the constitutive activation of the Wnt signaling pathway. The aberrant activation of Wnt signaling is a known driver of cell proliferation and tumorigenesis in Wilms tumors, making Wilms6 a valuable tool for investigating the role of Wnt pathway dysregulation in tumors with WT1 mutations. Phenotypically, Wilms6 cells display a mesenchymal morphology, with strong expression of vimentin and absence of epithelial markers such as cytokeratin, reflecting the stromal nature of the original tumor. These cells have been shown to possess limited but notable differentiation potential, including the ability to differentiate into muscle-like cells under specific conditions, which mirrors the mesenchymal differentiation observed in some Wilms tumors. Proteomic studies of Wilms6 have identified the activation of multiple receptor tyrosine kinases (RTKs), including PDGFRbeta and AXL, which are involved in promoting cell survival, proliferation, and migration. The downstream activation of signaling pathways such as MAPK and PI3K/AKT further underscores the aggressive nature of this cell line. Overall, the Wilms6 cell line serves as a crucial model for exploring the molecular mechanisms underlying Wilms tumor development, particularly in cases of complete WT1 loss combined with Wnt signaling activation. Its genetic and phenotypic characteristics make it an excellent platform for studying the interplay between WT1 deficiency and aberrant signaling pathways, providing insights into potential therapeutic targets for this aggressive tumor type. Organism: Human Tissue: Kidney Disease: Wilms tumor Age: 15 months Gender: Male Ethnicity: Caucasian Morphology: Spindle-shaped Cell Type: Wilms cells Growth Properties: Adherent Citation: Wilms6 (Cytion catalog number 300415) Biosafety Level: 1 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_A5SI Mutational Profile: WT1 mutation status: homozygous c.1168C>T, p.R390x, LOH: 11p11-11pter, CTNNB1 mutation status: homozygous del TCT, p.DS45 Culture Medium: MSCGM kit (from Lonza) Dissociation Reagent: Accutase Subculturing: Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 3: 860015.0 Required Product 4: 830100.0